| |
|
|
|
CytomX Therapeutics Inc.  
|
|
8.525 0.215 (0.03%) |
07-10 16:00 |
|
Open: |
8.3 |
Pre close: |
8.31 |
Target:
|
10.61
|
|
High: |
8.77 |
Low: |
8.29 |
Resistance:
|
9.08
10.61
|
|
Volume: |
394,735 |
Market Cap: |
391M |
Support:
|
8.00
7.33
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
8.33
 |
MACD |
MACD(12,26):
|
-0.12 |
|
MA(20): |
8.35 |
Signal(12,26,9): |
-0.18 |
|
MA(100): |
8.33 |
Stochastic Oscillator |
%K(14,3):
|
38.63 |
|
MA(250): |
8.09  |
%D(3): |
33.98 |
|
Average Volume(K) |
3-Month: |
64851
|
52-Week |
High:
|
15.43 |
|
10-Days: |
38441 |
Low: |
3.60 |
|
RSI |
RSI(14):
|
50.40 |
Change(%): |
-27.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.670 |
Return on Equity (ttm) |
-78.9 |
Shares Out. (M) |
45.92 |
|
EPS Est. Current Year |
-1.490 |
Return on Assets (ttm) |
-13.8 |
Shares Float (M) |
37.17 |
|
EPS Est. Next Year |
-1.410 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.30 |
|
EPS Est. Next Quarter |
-0.410 |
Qtrly Rev. Growth |
68.2 |
% Held by Institutions |
84.32 |
|
Forward EPS |
-2.260 |
Gross Profit (p.s.) |
1.252 |
Shares Short (K) |
1680 |
|
Book Value (p.s.) |
1.520 |
EBITDA (p.s.) |
-2.059 |
P/E |
-5.10 |
|
Sales Per Share |
1.690 |
Qtrly Earnings Growth |
0.00 |
P/BV |
5.61 |
|
Profit Margin |
-97.82 |
Operating Cash Flow
(M) |
-151.19 |
P/S |
5.04 |
|
Operating Margin |
-125.16 |
Levered Free Cash Flow
(M) |
-177.14 |
P/CF |
-2.59 |
|
|
|
|
|
|
